Respiratory medications: a nursing reference guide

Respiratory pharmacology is high-yield content for both NCLEX and clinical practice. Nurses managing patients with asthma, COPD, and other respiratory conditions administer these drugs daily — and must understand not only the drug’s mechanism but when to use it, when to hold it, and what patient education matters most. A nurse who confuses a rescue inhaler with a maintenance inhaler, or misses the early signs of theophylline toxicity, is a safety risk to their patient.

This reference covers six major drug classes: bronchodilators (short- and long-acting beta-2 agonists), anticholinergics, inhaled corticosteroids, combination inhalers, methylxanthines, leukotriene modifiers, and mucolytics. For integrated clinical coverage, pair this guide with the asthma nursing reference, the COPD nursing guide, and the ABG interpretation guide. For broader pharmacology context, see the drug classifications guide and the cardiovascular medications reference.

Fast-scan: respiratory drug class overview

Bronchodilators: SABAs and LABAs

Bronchodilators work by relaxing bronchial smooth muscle, widening the airway and reducing resistance to airflow. They are the cornerstone of asthma and COPD management and represent one of the highest-yield drug categories for NCLEX respiratory questions. The critical distinction nurses must understand is the difference between rescue medications (SABAs) and maintenance medications (LABAs) — these are not interchangeable.

Short-acting beta-2 agonists (SABAs)

Mechanism: SABAs bind selectively to beta-2 adrenergic receptors in bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP. This relaxes smooth muscle and dilates the airways within minutes.

Prototype drug: Albuterol (also sold as ProAir, Ventolin, Proventil). Levalbuterol (Xopenex) is the R-enantiomer of albuterol with a slightly lower side-effect profile at equivalent doses.

Pharmacokinetics:

• Onset: 5–15 minutes (inhaled)
• Peak effect: 30–60 minutes
• Duration: 4–6 hours

Indications: Acute bronchospasm (asthma attack, COPD exacerbation), exercise-induced bronchospasm (taken 15 minutes before activity), adjunct in anaphylaxis-related bronchospasm.

Key nursing considerations:

Rescue, not maintenance — Albuterol is prescribed for as-needed use. A patient using their rescue inhaler more than twice per week (for symptoms, not exercise) has inadequately controlled asthma and needs their maintenance regimen escalated — this is a clinical flag and an NCLEX-tested concept.

Side effects — Tachycardia and palpitations are the most common systemic effects. Albuterol stimulates beta-1 receptors to a limited degree, raising heart rate. Monitor HR before and after nebulized treatments in patients with cardiac disease. Tremor, nervousness, and hypokalemia (especially with high-dose nebulization) are also reported.

Hypokalemia risk — High-dose or frequent albuterol drives potassium into cells via the Na/K-ATPase pump, dropping serum potassium. In patients with cardiac conditions or on digoxin, this electrolyte shift can provoke arrhythmias.

Patient education: Shake the MDI before use; prime the inhaler if new or unused for 2+ weeks; wait 1 minute between puffs; breathe in slowly and hold for 10 seconds after each puff. Rinse the mouthpiece weekly.

Long-acting beta-2 agonists (LABAs)

Mechanism: Same receptor as SABAs but bind with higher affinity and a longer duration. They do not work fast enough to rescue acute bronchospasm — onset is 15–30 minutes for formoterol (the fastest LABA) and up to 30–60 minutes for salmeterol.

Prototype drugs: Salmeterol (Serevent Diskus) — 12-hour duration, twice daily. Formoterol (Foradil, Perforomist) — 12-hour duration, also used in nebulized form for COPD.

Duration: 12 hours for both salmeterol and formoterol.

Critical FDA black box warning (asthma): LABAs must not be used as monotherapy for asthma. When used alone in asthma patients, they increase the risk of asthma-related death. In clinical practice and on NCLEX, LABAs are always combined with an inhaled corticosteroid in asthma management. This is a non-negotiable safety rule. The exception: in COPD, LABAs may be used without ICS.

Indications: Maintenance therapy for moderate-to-severe asthma (always with ICS), COPD maintenance (may be used alone), exercise-induced bronchospasm prevention (salmeterol).

Key nursing considerations:

• Never use a LABA as a rescue inhaler — the onset is too slow for acute attacks
• Educate patients that they will not feel immediate relief; these inhalers work over time
• If a patient is prescribed a LABA inhaler without an ICS (in asthma), flag this to the prescriber — it violates safety guidelines

Anticholinergics (ipratropium and tiotropium)

Anticholinergic bronchodilators block muscarinic acetylcholine receptors in the airways, preventing bronchoconstriction triggered by parasympathetic stimulation. They are particularly effective in COPD, where cholinergic tone plays a larger role in airway narrowing than in asthma. Anticholinergics do not target the same mechanism as beta agonists, which means they can be combined with SABAs for additive bronchodilation — a common approach in COPD exacerbations.

Ipratropium (Atrovent) — short-acting

Duration: 4–6 hours; administered 3–4 times daily via MDI or nebulizer.

Primary use: COPD maintenance, acute COPD exacerbation (often combined with albuterol in dual-nebulization). Also used as an adjunct in severe asthma exacerbations.

Key side effects:

• Dry mouth — Most common complaint; manageable with frequent sips of water
• Urinary retention — Clinically relevant in older male patients with benign prostatic hyperplasia (BPH)
• Constipation — From reduced GI motility
• Blurred vision — If the aerosol contacts the eyes (particularly with nebulizer mask use); instruct patients to keep their eyes closed or use a mouthpiece rather than a mask when possible

Contraindications: Use with caution in patients with glaucoma (especially narrow-angle glaucoma) — aerosolized anticholinergics can raise intraocular pressure if they contact the eyes. Not contraindicated in BPH but requires monitoring.

Tiotropium (Spiriva) — long-acting (LAMA)

Duration: 24 hours; once-daily dosing. This is the primary COPD maintenance anticholinergic and is one of the most prescribed drugs in COPD management.

Delivery device: HandiHaler (capsule pierced inside device) or Respimat (soft-mist inhaler). Patients must not swallow the capsule — it is for inhalation only. This is a common patient education error and tested on NCLEX.

Key considerations: Same anticholinergic side effect profile as ipratropium. Monitor for urinary retention, dry mouth, and constipation. Once-daily dosing improves adherence. Do not use in acute rescue — onset too slow.

Inhaled corticosteroids (ICS)

Inhaled corticosteroids are the most effective long-term maintenance therapy for persistent asthma. They reduce airway inflammation, decrease mucus production, and decrease bronchial hyperresponsiveness. They do not bronchodilate — they modify the inflammatory process that drives asthma over time.

Prototype drugs: Fluticasone (Flovent), budesonide (Pulmicort), beclomethasone (QVAR), mometasone (Asmanex), ciclesonide (Alvesco).

Mechanism: Corticosteroids bind to intracellular glucocorticoid receptors, suppressing the transcription of pro-inflammatory cytokines (IL-4, IL-5, IL-13), reducing eosinophilic inflammation, and decreasing mast cell activation in the airway mucosa.

Maintenance, not rescue: ICS inhalers have no immediate bronchodilating effect. Patients must understand that taking their ICS during an acute attack provides no benefit. The rescue inhaler (SABA) is for acute symptoms; the ICS is taken consistently on schedule to prevent attacks.

Critical side effects and nursing considerations:

Oral candidiasis (thrush) — The most common and preventable local side effect. Corticosteroid particles deposited in the oropharynx suppress local immunity, allowing Candida overgrowth. Prevention: always rinse the mouth with water and spit after each ICS dose. This is a mandatory patient education point and frequently tested on NCLEX. Spacers (valved holding chambers) also reduce oropharyngeal deposition.

Dysphonia (hoarse voice) — Steroid deposition on the vocal cords can cause hoarseness. Spacers reduce this risk.

Systemic effects (rare at standard doses) — At high doses or with poorly designed delivery, some systemic absorption occurs. In children, growth suppression has been documented at high doses. Adrenal suppression is a concern primarily with high-dose, long-term ICS use. Monitor for Cushing-like features in patients on high-dose therapy.

Patient education essentials:

1. Take every day as prescribed — benefits build over weeks
2. Rinse mouth and spit after every use
3. Use a spacer if prescribed — it improves delivery and reduces side effects
4. Report signs of oral thrush: white patches in the mouth, sore throat
5. Do not stop abruptly — taper under provider guidance if discontinuing

Combination inhalers (LABA + ICS)

Combination inhalers pair a LABA with an inhaled corticosteroid in a single device, simplifying regimens and improving adherence. They are first-line for moderate-to-severe asthma requiring both a maintenance bronchodilator and anti-inflammatory therapy, and a standard maintenance option in COPD.

Common combinations:

• Fluticasone/salmeterol (Advair Diskus, Advair HFA)
• Budesonide/formoterol (Symbicort)
• Mometasone/formoterol (Dulera)
• Fluticasone/vilanterol (Breo Ellipta) — once-daily, primarily for COPD

NCLEX-critical facts:

The black box warning for LABA monotherapy in asthma applies to the LABA component of combination inhalers when used without adequate ICS. However, combination products — where the ICS is built in — are the preferred and safe way to use LABAs in asthma. The key distinction: never use a LABA-only inhaler in asthma; combination (LABA+ICS) inhalers are appropriate.

Asthma vs COPD use: In asthma, combination inhalers are reserved for patients who remain uncontrolled on ICS alone. In COPD, LABA+ICS combinations are appropriate for patients with frequent exacerbations, especially those with eosinophilic inflammation. Some COPD patients do well on LABA alone or LABA+LAMA without ICS.

Key nursing education points: These are maintenance inhalers — not rescue. Patients should still have a separate SABA for acute symptoms. Teach the same oral rinsing habit as with ICS-only inhalers.

Methylxanthines: theophylline

Theophylline is a bronchodilator and respiratory stimulant from the methylxanthine class. It was a mainstay of asthma therapy before inhaled medications became standard, but it has largely been displaced to adjunct status because of its narrow therapeutic index and significant drug interaction profile.

Mechanism: Theophylline inhibits phosphodiesterase, increasing intracellular cAMP, and antagonizes adenosine receptors. The combined effect is bronchodilation and mild stimulation of the respiratory drive — useful in apnea of prematurity (where caffeine, a related methylxanthine, is now preferred).

Therapeutic drug monitoring: The therapeutic serum range is 10–20 mcg/mL. This is a narrow window, and levels above 20 mcg/mL produce toxicity. Routine serum level monitoring is mandatory.

Signs of theophylline toxicity (in order of increasing severity):

1. Nausea, vomiting, abdominal pain
2. Headache, restlessness, insomnia
3. Tachycardia, palpitations
4. Seizures (at levels above 30 mcg/mL)
5. Ventricular arrhythmias

Drug interactions: Many common drugs alter theophylline metabolism via CYP1A2. Drugs that increase theophylline levels (toxicity risk): ciprofloxacin, erythromycin, cimetidine. Drugs that decrease theophylline levels: rifampin, phenobarbital, phenytoin. Smoking induces CYP1A2 and lowers theophylline levels — patients who quit smoking during therapy may develop toxicity.

NCLEX nursing priority: A patient on theophylline reporting nausea, vomiting, and a heart rate of 118 bpm should have a serum theophylline level checked immediately — this presentation pattern is classic early-to-moderate toxicity.

Leukotriene modifiers

Leukotriene modifiers block the inflammatory pathway driven by leukotrienes — lipid mediators released by mast cells and eosinophils that cause bronchoconstriction, mucus hypersecretion, and airway edema. They are oral medications used for asthma maintenance and allergic rhinitis, offering a non-inhaled alternative particularly useful in patients with poor inhaler technique or concurrent allergic disease.

Drug names:

• Leukotriene receptor antagonists (LTRAs): Montelukast (Singulair), zafirlukast (Accolate) — block the cysteinyl leukotriene receptor (CysLT1)
• Leukotriene synthesis inhibitor: Zileuton (Zyflo) — inhibits 5-lipoxygenase, blocking leukotriene production at the source (less commonly prescribed due to liver toxicity risk)

Indications: Mild persistent asthma maintenance, aspirin-exacerbated respiratory disease (AERD), allergic rhinitis (montelukast).

Key considerations:

Aspirin-exacerbated respiratory disease (AERD) — Patients who develop bronchospasm with aspirin or NSAIDs have overactive leukotriene pathways. Leukotriene modifiers are particularly effective in this population.

Neuropsychiatric black box warning (montelukast): The FDA added a black box warning in 2020 for montelukast. Documented side effects include agitation, aggressive behavior, depression, insomnia, suicidal ideation and behavior. This warning applies to all patients — adults and children — and nurses must educate patients and families to report mood or behavioral changes promptly. Given these risks, montelukast should be reserved for patients who cannot tolerate or effectively use ICS, or those with concurrent allergic rhinitis.

Zafirlukast — Requires dosing on an empty stomach (food reduces absorption by 40%). Must monitor liver function — hepatotoxicity is a rare but documented risk.

Not rescue medications — Leukotriene modifiers build effect over days to weeks. They have no role in acute bronchospasm.

Mucolytics and expectorants

Mucolytics and expectorants target the viscosity of airway secretions, making it easier for patients to clear mucus. They are particularly relevant in COPD, cystic fibrosis (CF), and acute respiratory conditions where thick secretions impair airway clearance.

N-acetylcysteine (NAC)

N-acetylcysteine (Mucomyst) breaks disulfide bonds in mucus glycoproteins, reducing viscosity and making secretions easier to expectorate. It is administered via nebulization.

Critical nursing consideration: NAC can trigger bronchospasm, particularly in patients with reactive airway disease. Always have a bronchodilator (albuterol) available when administering nebulized NAC, and assess the patient’s airway response during the treatment. In some protocols, albuterol is pre-administered before NAC nebulization.

Second use — acetaminophen overdose: NAC is the antidote for acetaminophen (Tylenol) toxicity. It replenishes hepatic glutathione stores and prevents liver failure. This dual role is commonly tested on NCLEX.

Guaifenesin (Mucinex)

Guaifenesin is an expectorant that increases the volume of respiratory tract secretions, lowering their viscosity and facilitating mucociliary clearance. It is an OTC medication used in acute and chronic respiratory conditions.

Nursing education: Adequate hydration amplifies the effect of guaifenesin — patients should drink 8+ glasses of water daily. It does not suppress cough; it makes cough more productive.

Dornase alfa (Pulmozyme)

Dornase alfa is a recombinant human DNase used specifically in cystic fibrosis. It cleaves extracellular DNA — which accumulates in CF airway secretions from neutrophil breakdown — substantially reducing mucus viscosity.

CF-specific use: Administered via nebulizer once or twice daily. It is not indicated for non-CF patients. Storage: must be refrigerated and protected from light.

NCLEX clinical tips for respiratory medications

NCLEX questions on respiratory medications test clinical reasoning, not just drug recall. These are the priority frameworks that appear most frequently.

Rescue vs maintenance — the most tested concept

Every NCLEX test plan includes questions that hinge on distinguishing rescue from maintenance inhalers. The decision tree:

• Patient having an acute attack → SABA first (albuterol)
• Patient using SABA more than twice per week for symptoms → flag for provider — maintenance therapy needs escalation
• Patient reaches for their ICS during an acute attack → patient education deficiency — teach correct rescue use
• Patient on LABA without ICS (asthma) → safety concern — flag to prescriber

ICS patient education priorities

The NCLEX frequently presents a scenario where a patient on ICS has developed oral thrush, then asks what the nurse should teach to prevent recurrence. The answer: rinse the mouth with water and spit after every dose. The follow-up education: use a spacer device.

Theophylline toxicity — recognize the pattern

If the NCLEX presents a patient on theophylline with nausea, vomiting, and tachycardia: check the serum level immediately. Toxicity is suspected when levels exceed 20 mcg/mL. Drug interactions are a common NCLEX mechanism — a patient started on ciprofloxacin while taking theophylline may develop toxicity as ciprofloxacin inhibits theophylline metabolism.

Anticholinergic side effects in context

Tiotropium and ipratropium questions often involve older adult patients with BPH or glaucoma. Key teaching points: dry mouth is expected and manageable; report difficulty urinating; avoid aerosol contact with eyes.

Montelukast behavioral changes

Post-2020 NCLEX content increasingly tests the FDA black box warning for montelukast. If a patient’s family reports the patient has become irritable, aggressive, or depressed since starting the drug, the priority action is to notify the provider — the drug may need to be discontinued.

Inhaler technique errors

Device-specific errors are patient education fodder for NCLEX:

• MDI without spacer: patient actuates before inhaling, losing most of the dose to the mouth and throat
• Tiotropium HandiHaler: patient swallows the capsule instead of using the device
• DPI (dry powder inhaler like Advair Diskus or Spiriva): patient exhales into the device, wetting the powder and reducing dose delivery

When NCLEX asks what the nurse should evaluate to determine whether inhaler therapy is effective, the answer often starts with technique — because poor technique is the most common reason inhaler therapy fails.

Related references

• Asthma nursing reference — pathophysiology, assessment, and management
• COPD nursing guide — disease progression, exacerbation management, oxygen therapy
• ABG interpretation guide — interpreting blood gas findings in respiratory failure
• Drug classifications nursing guide — pharmacology foundations for NCLEX
• Cardiovascular medications nursing reference — antihypertensives, antiarrhythmics, digoxin